Dapagliflozin in Patients with Chronic Kidney Disease

New England Journal of Medicine - Tập 383 Số 15 - Trang 1436-1446 - 2020
Hiddo J.L. Heerspink1,2, Bergur V. Stefánsson3, Ricardo Correa–Rotter4, Glenn M. Chertow5, Tom Greene6, Fan Fan Hou7, Johannes F.E. Mann8, John J.V. McMurray, Magnus Lindberg3, Peter Rossing9, C. David Sjöström3, Roberto D. Toto10, Anna-Maria Langkilde3, David C. Wheeler11,2
1Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2George Institute for Global Health, Sydney
3Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
4National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City
5Departments of Medicine and Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA
6Study Design and Biostatistics Center, University of Utah Health Sciences, Salt Lake City
7Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, Guangzhou, China
8KfH Kidney Center, Munich, and Department of Medicine 4, University of Erlangen–Nuremberg, Erlangen — both in Germany
9Department of Clinical Medicine, University of Copenhagen, Copenhagen — both in Denmark
10Department of Internal Medicine, UT Southwestern Medical Center, Dallas
11Department of Renal Medicine, University College London, London

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(16)32064-5

10.1681/ASN.2018050515

10.1016/S0140-6736(98)10363-X

10.1056/NEJMoa053107

10.1056/NEJMoa011161

10.1056/NEJMoa011303

10.1056/NEJMoa1515920

10.1056/NEJMoa1611925

10.1056/NEJMoa1812389

10.1056/NEJMoa1811744

10.1016/S2213-8587(20)30162-5

10.1016/j.kint.2017.12.027

10.1016/j.kint.2019.09.013

10.1093/ndt/gfz290

10.1093/ndt/gfaa234

10.1016/S2213-8587(19)30256-6

10.1016/S0140-6736(20)30045-3

10.1056/NEJMoa1911303

10.1056/NEJMoa1504720

10.1016/S2213-8587(19)30086-5